Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats

Archives of Pharmacal Research

Volumn 30, Issue 1, 2007, Pages 90-95

  Hong, Soon Pyo ^a   Chang, Kyoung Sig ^a   Choi, Dong Hyun ^a   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

Author keywords

Atorvastatin; Desacetyldiltiazem; Diltiazem; Pharmacokinetics; Rat

Indexed keywords

ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; DEACETYLDILTIAZEM; DILTIAZEM; DRUG DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOTRANSFORMATION; BLOOD; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLIC CLEARANCE RATE; ORAL DRUG ADMINISTRATION; RAT; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALF-LIFE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33846820045     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02977783     Document Type: Article

References (37)

1. Benet, L. Z., Cummins, C. L., and Wu, C. Y., Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab., 4, 393-398 (2003).
2. Bogman, K., Peyer, A. K., Torok, M., Kusters, E., and Drewe, J., HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol., 132, 1183-1192 (2001).
3. Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., and Whitfield, L., Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol., 40, 91-98 (2000).
4. Buckley, M. M-T., Grant, S. M., Goa, K. L., McTabish, D., and Sorkin, E. M., Diltiazem: A reappraisal of its pharmacological properties and therapeutic use. Drugs, 39, 757-806 (1990).
5. Chaffman, M. and Brogden., R. N., Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs, 29, 387-454 (1985).
6. Cummins, C. L., Jacobsen, W., and Benet, L. Z., Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 300, 1036-1045 (2002).
7. Gan, L. S. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W., and Thakker. D. R., CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos., 24, 344-349 (1996).
8. Goebel, K. J. and Kolle, E. U., High performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. J. Chromatogr., 345, 355-363 (1985).
9. Gottesman, M. M. and Pastan, I., Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62, 385-427 (1993).
10. Homsy, W., Caille, G., and du Souich, P., The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit. Pharm. Res., 12, 1722-1726 (1995a).
11. Homsy, W., Lefebvre, M., Caille, G., and du Souich, P., Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies. Pharm. Res., 12, 609-614 (1995b).
12. Ito, K., Kusuhara, H., and Sugiyama, Y., Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res., 16, 225-231 (1999).
13. Kantola, T., Kivisto, K .T., and Neuvonen, P. J., Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther., 64, 177-82 (1998a).
14. Kantola, T., Krivisto, K. T., and Nenvonen, P. J., Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther., 64, 58-65 (1998b)
15. Kolars, J. C., Schmiedlin-Ren, P., Dobbins, W. O., Schuetz, J., Wrighton, S. A., and Watkins. P. B., Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology, 102, 1186-1198 (1992).
16. Lea, A. P. and McTavish, D., Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs, 53, 828-847 (1997)
17. Lee, Y. H., Lee, M. H., and Shim, C. K., Pharmacokinetics of diltiazem and deacetyldiltiazem in rats. Int. J. Pharm., 76, 71-76 (1991).
18. Lefebvre, M., Homsy, W., Caille, G., and du Souich, P., First-pass metabolism of diltiazem in anesthetized rabbits: role of extrahepatic organs. Pharm. Res., 13, 124-128 (1996).
19. Lennernas, H., Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet., 42, 1141-1160 (2003)
20. Lilja, J. J., Kivisto, K. T., and Neuvonen, P. J., Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin. Pharmacol. The., 66, 118-127 (1999)
21. Mc Donnell, C. G., Harte, S., O'Driscoll, J., O'Loughlin, C., Van Pelt, F. N., and Shorten, G. D., The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam. Anaesthesia, 58, 899-904 (2003).
22. Mousa, O., Brater, D. C., Sunblad, K. J., and Hall, S. D., The interaction of diltiazem with simvastatin. Clin. Pharmacol. Ther., 67, 267-274 (2000).
23. Narita, H., Otsuka, M., Yabana, H., and Nagao, T., Hypotensive response of spontaneously hypertensive rats to centrally administered diltiazem and its metabolites: in relevance to the hypotensive action by oral administration. J. Pharmacobiodyn., 9, 547-53 (1986).
24. Pichard, L., Gillet, G., Fabre, I., Dalet-Beluche, I., Bonfils, C., Thenot, J. P., and Maurel, P., Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab. Dispos., 18, 711-719 (1990).
25. Renders, L., Mayer-Kadner, I., Koch, C., Scharffe, S., Burkhardt, K., Veelken, R., Schmieder, R. E., and Hauser, I. A., Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol. Dial. Transplant., 16, 141-146 (2001).
26. Rocci, M. L. and Jusko, W. J., LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine, 16, 203 (1983).
27. Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., and Komano, T., P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS. Lett., 324, 99-102 (1993).
28. Siedlik, P. H., Olson, S. C., Yang, B. B., and Stern, R. H., Erythromycin coadministration increases plasma atorvastatin concentrations. J. Clin. Pharmacol., 39, 501-504 (1999).
29. Wacher, V. H., Silverman, J. A., Zhang, Y., and Benet, L. Z., Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87, 1322-1330 (1998).
30. Wacher, V. J., Salphati, L., and Benet, L. Z., Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev., 46, 89-102 (2001).
31. Wang, E., Casciano, C. N., Clement, R. P., Johnson, and W. W., HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res., 18, 800-806 (2001).
32. Watkins, P. B., Wrighton, S. A., Schuetz, E. G., Molowa, D. T., and Guzelian, P. S., Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J. Clin. Invest., 80, 1029-1036 (1987).
33. Weir, M. R., Diltiazem: ten years of clinical experience in the treatment of hypertension. J. Clin. Pharmacol., 35, 220-232 (1995).
34. Wu, X., Whitheld, L. R., and Stewart, B. H., Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and proton-monocarboxylic acid co-transporter. Pharm. Res., 17, 209-215 (2000)
35. Yeung, P. K. Prescott, C., Haddad, C., Montague, T. J., McGregor, C., Quilliam, M. A., Xei, M., Li, R., Farmer, P., and Klassen., G. A., Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose. Eur. J. Drug Metab. Pharmacokinet., 18, 199-206 (1993).
36. Yeung, P. K., Feng, J. D. Z., and Buckley., S. J., Pharmacokinetics and hypotensive effect of diltiazem in rabbits: Comparison of diltiazem with its major metabolites. J, Pharm, Pharmacol., 50, 1247-1253 (1998).
37. Yusa, K. and Tsuruo, T., Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res., 49, 5002-5006 (1989).